Lysophosphatidic Acid (LPA): A Comprehensive Reference
1. Identity, Chemistry, and Natural Sources
Chemical Identity
Lysophosphatidic acid (LPA; 1- or 2-acyl-sn-glycerol-3-phosphate) is a bioactive phospholipid with diverse biological functions on many cell types. LPA is not a single entity but a family of naturally occurring glycerophospholipids composed of a glycerol backbone with an esterified single acyl chain and a phosphate group. LPA molecules' characteristics comprise a glycerol backbone with a phosphate group in the sn-3 position, a fatty acid chain, and a hydroxyl group in the sn-1 or sn-2 position.
Lysophospholipids are membrane-derived bioactive lipid mediators; they include lysophosphatidic acid (formally designated 1-acyl-2-hydroxy-sn-glycero-3-phosphate; LPA), sphingosine 1-phosphate (S1P), lysophosphatidylcholine (LPC), and sphingosylphosphorylcholine (SPC). The diversity of LPA as a class stems from variability in the attached fatty acyl chain. The term LPA covers several chemical species able to activate LPA receptors depending on the nature of the fatty acid side chain on the glycerol backbone. The most abundant LPA species in human plasma is LPA C18:2, with a fatty acid side chain of 18 carbon atoms including 2 unsaturated bonds.
LPA is a quantitatively minor lipid species compared to major phospholipid counterparts such as phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin. LPA is a small ubiquitous lipid found in vertebrate and nonvertebrate organisms that mediates diverse biological actions and demonstrates medicinal relevance.
Natural Occurrence and Food Sources
LPA is present in several biological fluids including serum, plasma, and aqueous humor, and can be secreted by several cell types including platelets, fibroblasts, adipocytes, and cancer cells. LPA is present in multiple body fluids, such as blood, saliva, and urine. LPA is present in plasma at concentrations in the range of 0.1–1.0 μM.
LPA, a potent bioactive phospholipid, is a natural component of food products like soy and egg yolk. LPA is mainly generated in blood platelets but is also highly abundant in foods such as soybean and egg yolk. Research has additionally quantified LPA precursors in plant foods: in a quantification study of phosphatidic acid (the metabolic precursor to LPA) across 38 foodstuffs and 3 herbs, vegetables belonging to Brassicaceae, such as cabbage leaves (700 nmol/g of wet weight) and Japanese radish leaves (570 nmol/g), contained higher amounts than other foodstuffs. Animal foodstuffs contained low amounts of the precursor (<60 nmol/g). Interestingly, leaves of Mallotus japonicus, a Japanese edible herb used for treatment of stomach ulcer, had the highest phosphatidic acid content (1,410 nmol/g) among those examined.
Researchers quantified LPA in 21 medicinal herbs used for treatment of gastrointestinal disorders, finding that half of them contained LPA at relatively high levels (40–240 μg/g) compared to soybean seed powder (4.6 μg/g). The LPA in peony (Paeonia lactiflora) root powder is highly concentrated in the lipid fraction.
Forms and Preparations
LPA itself does not have a history as an isolated, packaged dietary supplement in the traditional sense. Instead, it occurs naturally in foods and in the body as a lipid mediator. A glycolipoprotein called gintonin, isolated from ginseng (Panax ginseng), has been found to contain various components including ginseng major latex-like protein 151 (GLP151), ginseng ribonuclease-like storage protein, phosphatidic acids, and lysophosphatidic acid (LPA). Gintonin has been identified as a ligand of LPA receptor subtypes. Synthetic LPA analogs and metabolically stabilized LPA mimics (such as octadecenyl thiophosphate, or OTP) have also been studied in preclinical research as exogenous compounds targeting LPA receptors, though these are investigational tools rather than consumer supplements.
2. Historical and Traditional Context
Although the explicit identification and isolation of LPA is a relatively modern scientific achievement, substances rich in phospholipids and lysophospholipids have been used in traditional medicine for centuries. Ancient remedies often utilized egg yolk, soybeans, and other lecithin-rich foods — natural sources of LPA precursors — for their purported restorative and strengthening properties; these ingredients were incorporated into tonics aimed at promoting vitality, cognitive function, and overall wellness.
Regarding medicinal herbs, researchers studying 21 medicinal herbs used traditionally for treatment of gastrointestinal disorders found significant quantities of LPA in many of them, suggesting that plant-derived LPA may have contributed to the observed therapeutic effects of these traditional preparations, even if the specific role of LPA was not recognized at the time.
The ginseng-derived fraction gintonin provides a well-documented example of an LPA-containing natural product with a long traditional history. Ginseng (Panax ginseng C.A. Meyer) has been used in East Asian traditional medicine — particularly in Korean, Chinese, and Japanese practices — for thousands of years for its adaptogenic and restorative properties. Modern research has revealed that gintonin, an LPA-containing glycolipoprotein component of ginseng, likely mediates some of those traditional effects through LPA receptor signaling.
It should be noted that LPA was first identified as a bioactive lipid mediator involved in diverse physiological processes, such as cell proliferation, migration, and survival through modern biochemical science — formal isolation and characterization occurred in the 20th century — and no traditional healing system historically identified or intentionally administered LPA in isolation.
3. Biosynthesis, Key Metabolic Pathways, and Active Species
Endogenous Production
Unlike sphingosine 1-phosphate, a structurally similar bioactive lysophospholipid that is produced intracellularly, LPA is produced by multiple extracellular degradative routes. A plasma enzyme called autotaxin (ATX) is responsible for most LPA production in the body.
LPA can be generated via two general pathways: (i) one involves the generation of lysophospholipids (LPLs) from phospholipids (PLs) by phospholipase A1/A2 (PLA1/2), and transformation of LPLs to LPA by autotaxin (ATX)/lysophospholipase D; (ii) the other involves the formation of phosphatidic acids (PAs) from PLs by phospholipase D, or from diacylglycerol (DAG) by diacylglycerol kinase (DGK), and transformation of PA to LPA by PLA1/2.
ATX, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2) or lysophospholipase D, is a ~120 kDa protein that belongs to the ENPP family of enzymes; it is the only ENPP enzyme with lysophospholipase D activity and is responsible for the hydrolysis of lysophosphatidylcholine (LPC) to produce the bioactive lipid LPA.
LPA species are produced extracellularly as well as intracellularly through multiple mechanisms involving different enzymes and substrates. As intermediate products in the biosynthesis of triacylglycerol and phospholipids, LPA species are de novo synthesized from glycerol-3-phosphate and acyl-CoA by glycerophosphate acyltransferase activity in the mitochondria and endoplasmic reticulum.
Catabolism
LPA can be metabolized to monoacylglycerol (MAG) by lipid phosphate phosphatases LPP1–3 and lysophospholipases, a process that can be reversed by MAG kinase. LPA can also be removed by a variety of LPA acyltransferases (LPAATs).
The different enzymes involved in LPA synthesis (acyltransferases, phospholipases, kinases) and degradation (lysophospholipases, lipid-phosphatases) are of research interest, as are the molecules involved in LPA transport, including albumin, fatty acid binding proteins, gelsolin, and lipoproteins.
4. Receptors and Mechanisms of Action
G Protein-Coupled Receptors
LPA exhibits a wide variety of biological functions as a bioactive lysophospholipid through G-protein-coupled receptors specific to LPA. Currently at least six LPA receptors are identified, named LPA1 to LPA6, while the existence of other LPA receptors has been suggested.
LPA's functional roles are driven by extracellular signaling through at least six 7-transmembrane G protein-coupled receptors. These receptors (LPA1–6) signal through numerous effector pathways activated by heterotrimeric G proteins, including Gi/o, G12/13, Gq, and Gs.
LPA signals through at least six GPCRs (LPA1–6) that couple to different Gα proteins to elicit activation of Rho, PLC, Ras, PI3K, and adenylyl cyclase (AC), mediating diverse processes that are cell- and context-dependent.
The LPA1, LPA2, and LPA3 receptors belong to the endothelial differentiation gene family of GPCRs and show about 50% sequence homology to one another, whereas LPA4, LPA5, GPR87 (LPA6), and P2Y5 (LPA7) belong to purinergic receptors and share about 35% sequence homology.
Downstream Cellular Effects
Lysophospholipids affect fundamental cellular functions including cellular proliferation, differentiation, survival, migration, adhesion, invasion, and morphogenesis. These functions influence many biological processes including neurogenesis, angiogenesis, wound healing, immunity, and carcinogenesis.
LPA has a diverse range of physiological actions including effects on blood pressure, platelet activation, and smooth muscle contraction, and a variety of cellular effects including cell growth, cell rounding, neurite retraction, and actin stress fiber formation and cell migration.
From studies on knockout mice and hereditary diseases of these LPA receptors, it is now clear that LPA is involved in various biological processes including brain development and embryo implantation, as well as pathophysiological conditions including neuropathic pain and pulmonary and renal fibrosis.
5. Body Systems and Areas of Scientific Investigation
Nervous System Development and Pain
Lysophosphatidic acid (LPA) is essential for brain development and nervous system function, signaling through six different G-protein coupled receptors (LPAR1-6).
The bioactive lipid LPA, via activation of its receptors (LPARs), is thought to play a central role in both triggering and maintaining neuropathic pain. Following an acute nerve injury, excitatory neurotransmitters glutamate and substance P are released from primary afferent neurons leading to upregulated synthesis of lysophosphatidylcholine (LPC), the precursor for LPA production. LPC is converted to LPA by autotaxin (ATX), which can then activate macrophages/microglia and modulate neuronal functioning.
Upon nerve injury, newly produced LPC is converted to LPA by ATX, which is always present in cerebrospinal fluid. LPA then acts on LPA1 in myelin, inducing demyelination and the subsequent manifestation of pain.
LPA, as an initiator of neuropathic pain, causes allodynia. Pharmacological characterization of LPA-induced pain has been studied with clinically relevant drugs used for neuropathic pain, including antiepileptics, non-steroidal anti-inflammatory agents, analgesics, local anesthetics/antiarrhythmics, and antidepressants. This is entirely preclinical and animal-model evidence. There are no approved clinical interventions for neuropathic pain that target the LPA pathway as of the current literature.
Reproductive System
LPA through activating its G protein-coupled receptors (LPAR1–6) exerts diverse cellular effects that influence several physiological processes including reproductive function of the female. Studies in various species of animals and also in humans have identified important roles for receptor-mediated LPA signaling in multiple aspects of reproductive tract function, ranging from ovarian and uterine function, estrous cycle regulation, early embryo development, embryo implantation, decidualization, to pregnancy maintenance and parturition. LPA signaling can also have pathological consequences, influencing aspects of endometriosis and reproductive tissue-associated tumors.
Cardiovascular System
LPA has been found to accumulate in high concentrations in atherosclerotic lesions. It is a bioactive phospholipid produced by activated platelets and formed during the oxidation of LDL. Accumulating evidence suggests that this lipid mediator may serve as an important risk factor for development of atherosclerosis and thrombosis.
LPA is a weak activator of platelets from some, but not all, individuals and exerts migration-stimulating and proinflammatory actions on several classes of leukocytes. Among 70 patients with stable coronary artery disease, 99% of patients were identified as LPA responders, suggesting that LPA may be a pathophysiologically relevant mediator of cardiovascular disease in humans.
In humans, heritable variants of the PLPP3 gene encoding lipid phosphate phosphatase 3 (LPP3) — an enzyme that can dephosphorylate and inactivate LPA — are associated with inter-individual variability in coronary artery disease risk. The risk-associated variants disrupt regulatory elements that normally increase PLPP3 expression, suggesting that attenuated inactivation of LPA signaling may underlie increased risk of coronary artery disease.
Fibrosis (Pulmonary, Renal, Hepatic)
Lysophosphatidic acids have been implicated as potential mediators of fibroblast recruitment to the pulmonary airspace, pointing to possible involvement of LPA in the pathology of pulmonary fibrosis.
LPA accumulates in the serum of patients with systemic sclerosis (SSc), in bronchoalveolar lavage (BAL) fluid of patients suffering from idiopathic pulmonary fibrosis (IPF), and in human atherosclerotic plaques.
LPA signaling via specific LPA-producing enzymes and LPA receptors is involved in pathophysiological conditions including lung fibrosis. Upon lung injury, LPC and autotaxin (ATX) levels increase and activate the LPA1 receptor on fibroblasts in the alveolar compartment, which leads to the progression of fibrosis by depositing extracellular matrix (ECM) components.
Increased circulating LPA has been found in patients with chronic hepatitis C and liver fibrosis and in experimentally induced liver fibrosis.
Gastrointestinal System
LPA, a natural component of food products like soy and egg yolk, modulates a number of epithelial functions and has been shown to inhibit cholera toxin-induced diarrhea. The antidiarrheal effects of LPA are known to be mediated by inhibiting chloride secretion.
Research in intestinal epithelial cells demonstrates that LPA stimulates apical Cl⁻/OH⁻ exchange activity and surface levels of the DRA (downregulated in adenoma) protein. This increase in Cl⁻/OH⁻ exchange may contribute to the antidiarrheal effects of LPA.
LPA receptor 1 has been shown to regulate proliferation of intestinal epithelial cells, such that the absence of LPA1 mitigates the epithelial wound healing process. Evidence supports that LPA1 is important for the maintenance of epithelial barrier integrity.
Findings from cell studies suggest that LPA in the diet or from its digestion may contribute to the epithelial integrity of stomach mucosa by enhancement of prostaglandin E2 (PGE2) production via activation of LPA2.
The LPA in peony root powder is highly concentrated in the lipid fraction that ameliorates indomethacin-induced gastric ulcer in mice. Synthetic 18:1 LPA, peony root LPA, and peony root lipid enhanced prostaglandin E2 production in a gastric cancer cell line (MKN74 cells that express LPA2 abundantly). These materials also prevented indomethacin-induced cell death and stimulated the proliferation of MKN74 cells. This evidence is preclinical (mouse and cell-based).
Hair Follicle Biology and Skin
LPA receptors are known to be involved in biological effects including mitogenic effects on various cell types, hair follicle development, vascular development, regulation of embryo implantation, and spermatogenesis.
Gintonin, a lysophosphatidic acid receptor ligand from ginseng, can cause transient elevation of cytosolic Ca²⁺ levels in dermal papilla cells (DPCs), induce cell proliferation and release of VEGF, and stimulate hair growth in C57BL/6 mice at the hair follicle telogen, leading hair follicles to transition from early telogen to anagen phase. This is animal model evidence only; human clinical trials specifically targeting LPA in hair growth have not yet been reported in the peer-reviewed literature.
Regarding wound healing and skin, gintonin — an LPA receptor ligand — increased proliferation, migration, and scratch closure in human HaCaT keratinocytes, and also increased the release of vascular endothelial growth factor (VEGF) in those cells. Gintonin enhanced cell proliferation, migration, VEGF release, and wound closure in in vitro assays using HaCaT human skin keratinocytes, and promoted in vivo wound healing in a wounded mouse tail. These effects were demonstrated to be LPA-receptor-dependent, as blocking LPA receptors abolished the response.
Immune System and Inflammation
LPA has direct effects on inflammatory cells of both the innate and adaptive immune systems, including being a powerful stimulator of human neutrophil motility, causing an increase in binding of monocytes and neutrophils to human aortic endothelial cells, and activating human eosinophils. LPA increases the allostimulatory function of mature dendritic cells, inhibits their capacity to induce T helper 1 cell differentiation, and increases the ability of dendritic cells to polarize T cells to a Th2 phenotype.
LPA regulates physiological and pathological processes in numerous cell biological functions, including cell migration, apoptosis, and proliferation. However, continuous LPA-mediated insult can disrupt homeostasis and repair, leading to macrophage-related diseases such as inflammation, atherosclerosis, and fibrosis.
Cancer
LPA is a ubiquitous lysophospholipid and one of the main membrane-derived lipid signaling molecules. LPA acts as an autocrine/paracrine messenger through at least six GPCRs to induce various cellular processes including wound healing, differentiation, proliferation, migration, and survival. LPA receptors and autotaxin (ATX) are overexpressed in many cancers and impact several features of the disease, including cancer-related inflammation, development, and progression.
Lysophosphatidic acid is a bioactive lipid involved in fibrosis and in radiation-induced fibrosis as suggested in recent studies. LPA is also a well-described pro-oncogenic factor, involved in carcinogenesis processes including proliferation, survival, angiogenesis, invasion, and migration.
Neuropsychiatric and Neurodegenerative Diseases
The autotaxin enzyme that drives the synthesis of LPA, together with LPA levels, are enhanced in Alzheimer's disease (AD). In experimental models of AD, LPA leads to increased production of amyloid-β (Aβ) through PKC-mediated upregulation of β-secretase expression. However, other authors demonstrated that the administration of gintonin (an LPA-receptor-activating ligand) to transgenic AD mice reduced amyloid plaque deposition, increased hippocampal neurogenesis, and alleviated memory impairment. These are conflicting findings from animal models only, and no clinical evidence is available for LPA's role in AD treatment or prevention.
6. Scientific Evidence by Area of Use
6.1 Ovarian Cancer Biomarker — Strongest Human Clinical Evidence
The most clinically advanced human evidence for LPA concerns its utility as a serum/plasma biomarker for ovarian cancer detection.
In separate studies, LPA was found to be elevated in 90% of stage I ovarian cancer patients, and 100% of later-stage patients, with concentrations ranging between 1.3 and 50 μM being associated with the disease. LPA has been linked as a potential biomarker for ovarian cancer, with sensitivity and specificity of over 90%, with a cut-off of 1.3 μM for cancer patients.
LPA elevation correlated to the stage of the disease, with stage III and IV patients presenting higher LPA serum concentrations than stage I and II patients.
A case-control study provided further human evidence: ovarian cancer patients showed significantly higher plasma LPA levels compared to patients with benign tumors and healthy controls (all P < 0.05). LPA showed higher sensitivity and specificity in ovarian cancer (OC) diagnosis compared to CA-125, especially in early-stage OC.
A separate study using capillary electrophoresis with indirect UV detection in 133 patients (60 with ovarian cancer, 43 without ovarian pathology, 30 with benign tumors) over three years found: patients with ovarian cancer had a significantly higher plasma LPA level (median 16.99 μmol/L, range 4.53–43.21 μmol/L) compared with controls with no ovarian pathology (median 2.92 μmol/L, range 0.94–22.93 μmol/L) and patients with benign ovarian tumor (median 7.73 μmol/L, range 1.12–28.84 μmol/L) (p < 0.001).
Evidence assessment: This represents the strongest domain of clinical evidence for LPA as a measurable marker. Multiple independent case-control studies and meta-analyses have consistently shown elevated plasma/serum LPA in ovarian cancer patients. However, there is currently no clinically employable assay for this biomarker, limiting its routine clinical implementation despite the promising diagnostic data.
6.2 Pulmonary Fibrosis — Phase II Clinical Trials (Antagonist Approach)
The role of LPA in pulmonary fibrosis has progressed to human clinical trials, albeit through antagonism (blocking LPA activity) rather than supplementation. The LPA1 receptor antagonist BMS-986020 for idiopathic pulmonary fibrosis entered phase II clinical trials but was discontinued due to noticeable side effects. A potent small molecule autotaxin inhibitor that can dramatically inhibit LPA generation in blood after oral administration has been reported, and a selective LPA1 receptor antagonist was under development as a treatment for idiopathic pulmonary fibrosis.
Evidence assessment: The clinical trial evidence in pulmonary fibrosis pertains to LPA blockade as a therapeutic strategy, not LPA supplementation. The discontinuation of BMS-986020 due to side effects illustrates that modulating the LPA axis in humans is not without risk.
6.3 Systemic Sclerosis — Phase II Human Trial
The LPA1/3 receptor antagonist SAR100842 has been studied as a potential treatment for systemic sclerosis. Again, this evidence applies to LPA pathway antagonism in a disease context, not to LPA administration as a supplement.
6.4 Gastrointestinal Health — Preclinical and Animal Evidence
Multiple preclinical studies establish LPA as a gastrointestinal mucosal-protective agent, acting via LPA2 receptors. Apical application of lysophosphatidic acid (LPA), a growth-factor-like phospholipid, was shown to prevent or restore gastrointestinal disorders such as diarrhea and stomach ulcer in experimental animals. Because LPA is formed from phosphatidic acid (PA) by the activity of digestive phospholipase A2, PA is a potential component for dietary treatment of such GI disorders.
Published preclinical data further show that LPA in the gastrointestinal tract derived from foods such as soybean has been studied for its role in intestinal health. High levels of phospholipids have been detected in the colonic mucosa of patients with inflammatory bowel disease, and LPA significantly reduces the degree of inflammation and necrosis in a rat model of colitis.
Evidence assessment: Evidence is predominantly animal- and cell-based. There are no published randomized clinical trials directly testing oral LPA supplementation for gastrointestinal outcomes in humans. The mechanistic basis is well-characterized but human efficacy has not been established.
6.5 Neuropathic Pain — Preclinical Only
LPA, as an initiator of neuropathic pain, causes allodynia. Few studies have evaluated the pharmacological profile of LPA-induced pain. Animal studies have characterized LPA-induced pain models and tested various analgesics against them, providing mechanistic insight into neuropathic pain pathways. There are no published clinical trials using LPA as a therapeutic agent for pain conditions.
One exploratory human study is notable: a cross-sectional clinical study (PLoS One, 2018) identified LPA as associated with neuropathic pain intensity in humans, suggesting potential utility as a biomarker, though the study was explicitly described as exploratory. Evidence strength in this domain remains weak to preliminary.
6.6 Skin Wound Healing and Hair Growth — Primarily Preclinical
Evidence from in vitro and rodent models demonstrates LPA receptor signaling promotes keratinocyte proliferation, migration, and VEGF production, which are all relevant to wound closure. Gintonin enhanced cell proliferation, migration, VEGF release, and wound closure in in vitro assays using HaCaT human skin keratinocytes, and promoted in vivo wound healing in a wounded mouse tail. No clinical trials of LPA itself for wound healing or alopecia treatment in humans have been reported in the peer-reviewed literature.
6.7 Cardiovascular Risk — Epidemiological and Observational Human Data
LPA's role in cardiovascular disease is characterized primarily by its pathological accumulation. LPA metabolism and signaling are implicated in heritable risk of coronary artery disease. Genetic and pharmacological inhibition of these processes attenuate experimental atherosclerosis. LPA accumulates in atheromas, which may be a consequence of association with LDLs.
Evidence assessment: The cardiovascular evidence predominantly implicates elevated endogenous LPA as a risk factor, not a therapeutic candidate. There are no human trials of LPA supplementation for cardiovascular benefit.
7. Dosage Forms and Reported Concentrations
LPA as an isolated supplement does not have established dosage guidelines from any regulatory body (NIH, EMA, EFSA) or official pharmacopeia. The following reflects concentrations reported in research contexts only:
- Endogenous plasma concentrations: LPA is present in plasma at concentrations in the range of 0.1–1.0 μM under normal physiological conditions. Serum concentrations of LPA are higher than in plasma, which is probably caused by secretion of LPA by activated platelets.
- Ovarian cancer biomarker threshold: LPA concentrations ranging between 1.3 and 50 μM have been associated with ovarian cancer; a cut-off of 1.3 μM has been proposed for distinguishing cancer patients.
- In vitro wound healing (cell studies): In in vitro assays, LPA at 10 μM was used as a positive control for assessing keratinocyte proliferation and migration.
- Medicinal herb content: LPA content in medicinal herbs used for gastrointestinal disorders ranged from 40–240 μg/g in the herbs studied, compared to 4.6 μg/g in soybean seed powder.
- Animal dietary supplementation (preclinical): In rat studies, an LPA-rich soybean phospholipid mixture (LSP) was administered as 0.1% or 1% of high-fat diet to assess effects on colorectal tumorigenesis.
No human clinical dosing regimens for LPA as a standalone supplement have been established in the peer-reviewed literature.
8. Safety Considerations and Known Risks
Pro-Atherogenic and Thrombotic Effects of Unsaturated Species
A critical, source-backed safety consideration is the differential biological activity of LPA species by fatty acid composition. The thrombogenicity and atherogenicity of LPA crucially depends on the type of bondage of the fatty acyl chain to the glycerol backbone (ester or ether) and the saturation of the fatty acid; alkyl-LPA species are more potent platelet activators than the corresponding acyl-LPA species, and only unsaturated acyl-LPA species are atherogenic.
In mouse studies, supplementing chow with unsaturated (but not saturated) LPA resulted in aortic atherosclerosis. Unsaturated LPA was found to stimulate vascular smooth muscle cell (VSMC) de-differentiation through the activation of ERK and p38 MAPK, which is a hallmark in the development of atherosclerosis. Thus, naturally occurring unsaturated LPAs may act as atherogenic factors.
LPA may be involved in thrombus formation. LPA promoted human platelet activation by inducing platelet shape change and calcium mobilization.
Pro-Oncogenic and Tumorigenic Potential
LPA is a well-described pro-oncogenic factor, involved in carcinogenesis processes including proliferation, survival, angiogenesis, invasion, and migration. Oral administration of LPA has been shown to attenuate gastric ulceration in rats and mice but has also been found to aggravate intestinal tumorigenesis in mice. This dual protective (gastric) and potentially harmful (intestinal) profile observed in animal models warrants caution in extrapolating benefit.
Orally delivered LPA increased tumor burden, whereas the loss of LPA2 significantly decreased the progression of cancer in mouse models of familial adenomatous polyposis– and colitis-associated cancer. This is animal evidence only but raises a significant safety concern about oral LPA administration in individuals with predisposition to colorectal neoplasia.
Fibrosis
LPA has been implicated as a potential mediator of fibroblast recruitment to the pulmonary airspace, pointing to possible involvement of LPA in the pathology of pulmonary fibrosis. Elevated LPA signaling via LPA1 is mechanistically linked to fibrotic progression in the lung, kidney, and liver. The failure of the LPA1 antagonist BMS-986020 in clinical trials due to adverse effects underscores the difficulty of safely modulating this pathway.
Inflammatory and Immune Dysregulation
Continuous LPA-mediated insult can disrupt homeostasis and repair, leading to macrophage-related diseases such as inflammation, atherosclerosis, and fibrosis. LPA has direct effects on inflammatory cells of both the innate and adaptive immune systems, including being a powerful stimulator of human neutrophil motility and activating human eosinophils.
Reproductive System Risks
LPA signaling can have pathological consequences, influencing aspects of endometriosis and reproductive tissue-associated tumors. Given LPA's role in embryo implantation and uterine function, exogenous administration of LPA in women of reproductive age carries theoretical but unstudied risks.
Species- and Context-Dependent Effects
The measurement of total plasma LPA levels may not be sufficient to predict cardiovascular risk, because the thrombogenicity and atherogenicity of LPA crucially depends on the acyl chain type. Elevated levels of LPA during pregnancy, which is not associated with increased cardiovascular risk, are due to a rise predominantly of saturated LPA, such as LPA 16:0. This illustrates that the overall LPA level is insufficient for predicting health impact — the specific molecular species present is critical.
Lack of Clinical Safety Data
No human randomized clinical trials of oral LPA supplementation have been published, and therefore no formal safety, tolerability, pharmacokinetic, or drug interaction data in humans are available for LPA as a standalone dietary supplement. All safety inferences are extrapolated from endogenous biology, animal studies, and in vitro data.
References
Go back